Cancer medications approved by FDA accelerated approval program struggle to show benefit

12:07 EDT 30 May 2019 | 2 Minute Medicine

1. In this updated review of cancer medications that received Food and Drug Administration (FDA) accelerated approval program, only 20% of drugs demonstrate improved overall survival benefit. 2. Final FDA approval was commonly made based on surrogate measures. A substantial proportional of confirmatory trials are still ongoing or delayed despite initial approval. Evidence Rating Level: […]
Source: 2 Minute Medicine

More From BioPortfolio on "Cancer medications approved by FDA accelerated approval program struggle to show benefit"